SCHEMBL4152089

SCHEMBL4152089

NCc1ncccc1CCNC(=O)c1ccnc2[nH]c(-c3ccoc3)nc12

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 8/20 0.59
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
HIF1A Q16665 1/20 0.40
EGLN1 Q9GZT9 3/20 0.34
P2RX7 Q99572 2/20 0.34
RAD52 P43351 1/20 0.34
UHRF1 Q96T88 1/20 0.34
MTNR1A P48039 1/20 0.33
FLT3 P36888 1/20 0.33
PBK Q96KB5 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4157364 0.89 GSK3B (0.48) GSK3BMEN1NPC1RAB9AKMT2A
SCHEMBL4161634 0.87 GSK3B (0.76) GSK3BMEN1NPC1RAB9AKMT2A
SCHEMBL4152069 0.86 GSK3B (0.47) GSK3BMEN1NPC1RAB9AKMT2A
SCHEMBL4165066 0.85 GSK3B (0.57) GSK3BMEN1NPC1RAB9AKMT2A
SCHEMBL4169222 0.85 GSK3B (0.44) GSK3BMEN1NPC1RAB9AKMT2A
SCHEMBL4153458 0.85 GSK3B (0.42) GSK3BMEN1NPC1RAB9AKMT2A
SCHEMBL4958340 0.83 GSK3B (0.55) GSK3BMEN1NPC1RAB9AKMT2A
SCHEMBL4157073 0.82 GSK3B (0.54) GSK3BMEN1NPC1RAB9AKMT2A
SCHEMBL4161593 0.82 PBK (0.48) GSK3BMEN1NPC1RAB9AKMT2A
SCHEMBL4157297 0.82 GSK3B (0.49) GSK3BMEN1NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 GSK3B 1/4885MEN1 3177/4885NPC1 2497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.